Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Thinle Chodon Clear advanced filters

  • B-RAF is mutated in a large proportion of melanomas, and the first small molecule inhibitor has recently been approved for melanoma treatment. Here, by exome sequencing melanoma samples, Shi and colleagues show that B-RAF is amplified in tumours that have acquired resistance to the B-RAF inhibitor vemurafenib.

    • Hubing Shi
    • Gatien Moriceau
    • Roger S. Lo
    Research
    Nature Communications
    Volume: 3, P: 1-8

  • Current approaches for analyzing the functional heterogeneity of immune cells include ELISPOT and flow cytometry. Chao Ma et al. have introduced an antibody-barcode microchip platform that enables the measurement of a large panel of secreted proteins from several hundred single cells or small cell colonies in parallel. The platform offers advantages over existing technologies in terms of cost, multiplexing capacity, types of proteins that can be measured and experiments performed.

    • Chao Ma
    • Rong Fan
    • James R Heath
    Research
    Nature Medicine
    Volume: 17, P: 738-743

  • Recent data from early clinical trials in melanoma patients carrying mutations in the B-RAF gene have shown promising results with the B-RAF kinase inhibitor PLX4032; however, many patients eventually develop resistance to this treatment. Two papers now uncover possible mechanisms of resistance to PLX4032. One paper shows that upregulation of MAP3K8 (which encodes COT) can confer resistance of melanoma cells to B-RAF inhibitors, whereas another paper found that melanomas can acquire resistance due to mutations of N-RAS or increased expression of PDGFRβ. Each of these resistance mechanisms seems to apply to at least some patients on recent PLX4032 trial, whereas, surprisingly, so far no secondary B-RAF mutations have been observed.

    • Ramin Nazarian
    • Hubing Shi
    • Roger S. Lo
    Research
    Nature
    Volume: 468, P: 973-977